首页|Fecal microbiota transplantation for COVID-19; a potential emerging treatment strategy
Fecal microbiota transplantation for COVID-19; a potential emerging treatment strategy
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Elsevier
At the end of 2019， an emerging outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) that first reported from Wuhan， China。 The first manifestations of patients infected with SARS-CoV-2 was flu-like symptoms， while other type of manifestations， especially gastrointestinal manifestations were discovered recently。 As of June 2020， there is no specific drug or treatment strategy for COVID-19， a disease caused by SARSCoV-2， so different combination of antiviral drugs is currently being used。 Gut microbiota mostly consists of four phyla， including Firmicutes， Bacteroidetes， Proteobacteria， and Actinobacteria。 The interaction between gut microbiota and immune system through releasing some cytokines such as IL-1 beta， IL-2， IL-10， TNF-alpha， and IFN-gamma that play roles in the severity of COVID-19。 In this article， a new potential treatment for COVID-19 by fecal microbiota transplantation (FMT) is described。 FMT revealed promising results in different diseases， especially recurrent clostridium difficile infection， and it might reduce length of hospital admission and severity of the disease by modification of gut microbiota composition。
NSTL
Elsevier
